Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

BeiGene Out-Licenses TIGIT Inhibitor to Novartis in $2.8 Billion Agreement

publication date: Dec 20, 2021

Beijing BeiGene out-licensed ex-China rights for its TIGIT inhibitor to Novartis in a multi-faceted $2.8 billion deal. As part of the agreement, BeiGene will have rights to market five Novartis oncology drugs in China outside of China's largest cities. BeiGene will receive a $300 million upfront payment, a $600-$700 million option payment within two years. $745 million in regulatory milestones and $1.15 billion in sales milestones, It will also receive royalties on sales. In January, Novartis in-licensed BeiGene's PD-1 candidate in a similar deal. Currently, BeiGene is testing the TIGIT inhibitor paired with the PD-1 in several global trials for NSCLC and other cancers. More details....

Stock Symbols: (NSDQ: BGNE; HK: 06160; SHA: 688235) (NYSE: NVS)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here